Evidence map›Paper›PMID 26892631›Full record

ArticleLeukemia & lymphoma2016

Double- and triple-hit lymphomas can present with features suggestive of immaturity, including TdT expression, and create diagnostic challenges.

Laura Moench, Zohar Sachs, Garth Aasen, Michelle Dolan, Vanessa Dayton, Elizabeth L Courville

Abstract read
In one paragraph

Article in Leukemia & lymphoma, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. International Consensus Classification of acute lymphoblastic leukemia/lymphoma.Virchows Archiv : an international journal of pathology · 2023
    Review
  8. Review
  9. Article
  10. TdT Positive Lymphoma with MYC, BCL2 and BCL6 Rearrangements: A Review of Diagnosis and Treatment.Mediterranean journal of hematology and infectious diseases · 2022
    Article
  11. "Double hit" B-lymphoblastic lymphoma with concurrentTranslational cancer research · 2021
    Article
  12. Article
  13. Article
  14. High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019
    Article
  15. Review
  16. The clinicopathologic spectrum of mature aggressive B cell lymphomas.Virchows Archiv : an international journal of pathology · 2017
    Review
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Laura Moencha Department of Laboratory Medicine and Pathology , University of Minnesota , Minneapolis , MN , USA ;
Zohar Sachsb Department of Medicine, Division of Hematology, Oncology, and Transplantation , University of Minnesota , Minneapolis , MN , USA.
Garth Aasena Department of Laboratory Medicine and Pathology , University of Minnesota , Minneapolis , MN , USA ;
Michelle Dolana Department of Laboratory Medicine and Pathology , University of Minnesota , Minneapolis , MN , USA ;
Vanessa Daytona Department of Laboratory Medicine and Pathology , University of Minnesota , Minneapolis , MN , USA ;
Elizabeth L Courvillea Department of Laboratory Medicine and Pathology , University of Minnesota , Minneapolis , MN , USA ;
University of Minnesota · US

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
UNIVERSITY OF MINNESOTA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE (UMN CTSI)UL1RR033183 · NCRR · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2011 to 2011
$8.9M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)KL2TR000113 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$5.4M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)KL2RR033182 · NCRR · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2011 to 2011
$1.4M
NCATS NIH HHS KL2 TR000113NCATS NIH HHS UL1 TR000114NCRR NIH HHS KL2 RR033182NCRR NIH HHS UL1 RR033183
6 · The paper itself

Abstract

Double- and triple-hit lymphomas (DHL/THL) are aggressive B-cell neoplasms characterized by translocation of MYC with concurrent BCL2 and/or BCL6 translocation. In this retrospective study from one institution, we report clinicopathologic features of 13 cases (9 DHL/4 THL). The median age was 59 years (range 30-74) and patients included eight females and five males. Presentation included enlarging lymphadenopathy/masses (11 patients) and abnormal peripheral blood findings (2 patients). Features which raised the differential of an immature neoplasm included terminal deoxynucleotidyl transferase positivity (four cases, two THL/two DHL); dim CD45 expression (seven cases), lack of CD20 (two cases), or lack of surface immunoglobulin light chain (three cases) by flow cytometry; and blastoid morphology (two cases). We conclude that expression of TdT in a B-cell lymphoma with mature features or expression of surface light chain in a case otherwise suggestive of B-lymphoblastic leukemia/lymphoma should prompt an expedited evaluation for DHL/THL.

Indexed as

Biomarkers, TumorGene ExpressionAdultAgedCell Transformation, NeoplasticChromosome AberrationsCombined Modality TherapyDNA NucleotidylexotransferaseFemaleHumansImmunohistochemistryImmunophenotypingIn Situ Hybridization, FluorescenceLymphoma, B-CellMaleMiddle AgedBiomarkers, TumorDNA NucleotidylexotransferaseB-cell lymphoma unclassifiableB lymphoblastic leukemia/lymphomadiffuse large B-cell lymphomadouble-hit lymphomatriple-hit lymphoma

Identifiers

PMID26892631
PMCPMC6292197
OpenAlexW2310394681

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.